Virbac SA (VRBCF)
USD 324.0
(0.0%)
USD 324.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 422.66 Million EUR | -46.83% |
| 2022 | 794.99 Million EUR | 11.52% |
| 2021 | 712.85 Million EUR | 15.43% |
| 2020 | 617.56 Million EUR | -0.96% |
| 2019 | 623.53 Million EUR | 8.51% |
| 2018 | 574.64 Million EUR | 2.9% |
| 2017 | 558.44 Million EUR | -2.31% |
| 2016 | 571.67 Million EUR | 3.05% |
| 2015 | 554.77 Million EUR | 4.97% |
| 2014 | 528.51 Million EUR | 4.73% |
| 2013 | 504.66 Million EUR | 5.21% |
| 2012 | 479.65 Million EUR | 69.94% |
| 2011 | 282.25 Million EUR | -27.82% |
| 2010 | 391.05 Million EUR | 23.8% |
| 2009 | 315.87 Million EUR | 5.89% |
| 2008 | 298.3 Million EUR | 1.54% |
| 2007 | 293.79 Million EUR | 68.29% |
| 2006 | 174.57 Million EUR | 7.24% |
| 2005 | 162.79 Million EUR | -30.79% |
| 2004 | 235.22 Million EUR | -33.69% |
| 2003 | 354.75 Million EUR | -3.58% |
| 2002 | 367.93 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 241.4 Million EUR | 17.76% |
| 2024 Q2 | 241.4 Million EUR | 0.0% |
| 2023 FY | 422.66 Million EUR | -46.83% |
| 2023 Q2 | 209.44 Million EUR | 3.94% |
| 2023 Q3 | 205 Million EUR | -2.12% |
| 2023 Q4 | 205 Million EUR | 0.0% |
| 2023 Q1 | 201.5 Million EUR | 0.53% |
| 2022 Q1 | 200.09 Million EUR | 7.48% |
| 2022 Q2 | 226.82 Million EUR | 13.36% |
| 2022 Q3 | 197.4 Million EUR | -12.97% |
| 2022 Q4 | 200.44 Million EUR | 1.54% |
| 2022 FY | 794.99 Million EUR | 11.52% |
| 2021 Q4 | 186.16 Million EUR | 6.83% |
| 2021 FY | 712.85 Million EUR | 15.43% |
| 2021 Q2 | 192.2 Million EUR | 7.89% |
| 2021 Q1 | 178.15 Million EUR | 32.72% |
| 2021 Q3 | 174.25 Million EUR | -9.34% |
| 2020 FY | 617.56 Million EUR | -0.96% |
| 2020 Q2 | 157.14 Million EUR | -2.51% |
| 2020 Q1 | 161.19 Million EUR | 11.51% |
| 2020 Q4 | 134.23 Million EUR | -9.04% |
| 2020 Q3 | 147.58 Million EUR | -6.09% |
| 2019 Q2 | 155.61 Million EUR | 0.0% |
| 2019 Q4 | 144.56 Million EUR | -7.42% |
| 2019 FY | 623.53 Million EUR | 8.51% |
| 2019 Q3 | 156.14 Million EUR | 0.34% |
| 2019 Q1 | 155.61 Million EUR | 7.45% |
| 2018 Q3 | 144.83 Million EUR | 1.65% |
| 2018 FY | 574.64 Million EUR | 2.9% |
| 2018 Q2 | 142.48 Million EUR | 0.0% |
| 2018 Q1 | 142.48 Million EUR | 4.82% |
| 2018 Q4 | 144.83 Million EUR | 0.0% |
| 2017 Q3 | 135.93 Million EUR | -5.13% |
| 2017 Q2 | 143.28 Million EUR | 0.0% |
| 2017 Q4 | 135.93 Million EUR | 0.0% |
| 2017 FY | 558.44 Million EUR | -2.31% |
| 2017 Q1 | 143.28 Million EUR | 0.78% |
| 2016 Q4 | 142.17 Million EUR | 0.0% |
| 2016 Q1 | 143.66 Million EUR | 4.07% |
| 2016 FY | 571.67 Million EUR | 3.05% |
| 2016 Q3 | 142.17 Million EUR | -1.04% |
| 2016 Q2 | 143.66 Million EUR | 0.0% |
| 2015 Q2 | 139.34 Million EUR | 0.0% |
| 2015 FY | 554.77 Million EUR | 4.97% |
| 2015 Q4 | 138.04 Million EUR | 0.0% |
| 2015 Q3 | 138.04 Million EUR | -0.93% |
| 2015 Q1 | 139.34 Million EUR | 0.6% |
| 2014 Q1 | 125.74 Million EUR | 1.16% |
| 2014 FY | 528.51 Million EUR | 4.73% |
| 2014 Q3 | 138.5 Million EUR | 10.15% |
| 2014 Q4 | 138.5 Million EUR | 0.0% |
| 2014 Q2 | 125.74 Million EUR | 0.0% |
| 2013 Q1 | 128.02 Million EUR | 0.0% |
| 2013 FY | 504.66 Million EUR | 5.21% |
| 2013 Q3 | 124.3 Million EUR | -2.9% |
| 2013 Q2 | 128.02 Million EUR | 0.0% |
| 2013 Q4 | 124.3 Million EUR | 0.0% |
| 2012 FY | 479.65 Million EUR | 69.94% |
| 2011 FY | 282.25 Million EUR | -27.82% |
| 2010 FY | 391.05 Million EUR | 23.8% |
| 2009 FY | 315.87 Million EUR | 5.89% |
| 2008 FY | 298.3 Million EUR | 1.54% |
| 2007 FY | 293.79 Million EUR | 68.29% |
| 2006 FY | 174.57 Million EUR | 7.24% |
| 2005 FY | 162.79 Million EUR | -30.79% |
| 2004 FY | 235.22 Million EUR | -33.69% |
| 2003 FY | 354.75 Million EUR | -3.58% |
| 2002 FY | 367.93 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 98.782% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 98.768% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 98.598% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -3661.404% |
| Novartis AG | 34.18 Billion USD | 98.764% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | 43.149% |